Overview

IONLACE is a biotech-focused R&D company that builds and funds science projects in biotechnology, molecular biology, and advanced materials. It hires highly skilled, highly curious scientists—“rebel scientists”—and gives them resources and freedom to pursue ambitious, real-world-impact ideas. The company operates in innovation hubs like Stockholm and Copenhagen to accelerate research and development. Revenue comes from advancing R&D projects toward commercialization through patents, partnerships with larger companies, and market-ready products, as well as grants and venture funding. IONLACE differentiates itself by prioritizing rapid execution and bold, high-risk research led by top talent, aiming to stay ahead in a competitive field. Its goal is to shape the future of scientific and technological progress by turning breakthroughs into practical applications through collaborations, licensing, and new products.

Significant Headcount Growth

Simplify's Take

What believers are saying

• Pre-seed funding on November 18, 2023, accelerates AI protein platform development.
• Exhibiting at BIO 2026 enables partnerships with biotech and pharma leaders.
• Heartcore SynBio portfolio provides access to Nordic follow-on venture capital.

What critics are saying

• Genentech and Exscientia commoditize AI protein design within 12-24 months.
• Pre-seed funding fails to scale lab experiments versus Flagship Pioneering rivals.
• No Phase 2 programs block pharma partnerships in 12-24 months.

What makes Ionlace unique

• IONLACE builds modality-agnostic AI fusion protein platform for multi-specific biologics.
• Lab-in-the-loop AI generates high-resolution data from real experiments.
• Targets rebel scientists in Stockholm and Copenhagen for rapid innovation.

Help us improve and share your feedback! Did you find this helpful?

YesNo